Matson et al. (2018) compared the baseline microbiota composition of 42 patients with metastatic melanoma that received anti-PD-1 (n = 38) or anti-CTLA-4 (n = 4) immunotherapy [24]. The gene discussed is CTLA4; the disease is metastatic melanoma.